Imaging Technology

FEBRUARY 21, 2024

milla1cf Wed, 02/21/2024 - 18:58 February 21, 2024 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, is pleased to share the publication of promising early clinical data with 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1

Clinic 80

Clinic Radiopharmaceuticals Nuclear Medicine Hospital 80

AuntMinnie

JUNE 8, 2023

Radiopharmaceutical manufacturer SpectronRx and nuclear medicine drug distributo.

Radiopharmaceuticals 52

Radiopharmaceuticals Nuclear Medicine Clinic 52

Imaging Technology

JUNE 15, 2023

The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use.

Radiopharmaceuticals 86

Radiopharmaceuticals Pharmaceutical Nuclear Medicine PET Scan 86

Radiology Business

MAY 3, 2024

The Swiss drugmaker said the deal will bolster its research infrastructure and clinical supply capabilities, with an eye toward improving oncologic care.

Radiopharmaceuticals 87

Radiopharmaceuticals Clinic IT 87

Imaging Technology

JANUARY 5, 2024

milla1cf Fri, 01/05/2024 - 11:32 January 5, 2024 — NorthStar Medical Radioisotopes, LLC , a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, and Curadh MTR Inc. Chief Executive Officer of NorthStar Medical Radioisotopes.

Radiopharmaceuticals 52

Radiopharmaceuticals Medical Nuclear Medicine Pharmaceutical 52

Radiology Business

MAY 21, 2024

The Indianapolis-based drugmaker can hit the hefty total by reaching certain clinical, regulatory and commercial milestones.

Radiopharmaceuticals 86

Radiopharmaceuticals Clinic 86

Imaging Technology

SEPTEMBER 8, 2023

milla1cf Fri, 09/08/2023 - 16:25 September 8, 2023 — Positron Corporation , a leading molecular imaging medical device company, is pleased to announce that the Company will begin its clinical study of its Affinity PET-CT imaging device with Ochsner Clinic Foundation in New Orleans, LA. on September 18, 2023.

Clinic 95

Clinic Radiopharmaceuticals Medical Device IT 95

Imaging Technology

NOVEMBER 26, 2023

TeleDaaS specializes in delivering clinical-grade, precision-based dosimetry analysis and treatment plans to clinical research organizations (CROs) and pharmaceutical manufacturers. Radiopharmaceuticals are revolutionizing modern cancer treatment and precision dosimetry is a crucial component of this advanced therapy.

Clinic 54

Clinic Radiopharmaceuticals Radiosensitivity Pharmaceutical 54

AuntMinnie

MAY 1, 2023

Blue Earth Diagnostics is highlighting results from a clinical study that ha. prostate radiopharmaceutical licensing Blue Earth to highlight PET study results at ASTRO Blue Earth wins FDA nod for PSMA-PET tracer NDA

Clinic 52

Clinic Radiopharmaceuticals Diagnostic 52

Imaging Technology

AUGUST 29, 2023

Administration of the therapeutic dose took place as part of an ongoing Phase I/IIa theranostic clinical trial conducted by Clarity Pharmaceuticals to investigate the safety and efficacy of Cu-67 SARTATE in pediatric patients with high-risk neuroblastoma.

Pharmaceutical 75

Pharmaceutical Radiopharmaceuticals Clinic Medical 75

Imaging Technology

DECEMBER 6, 2023

and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today provided additional information regarding a March 2022 licensing and collaboration agreement between Philochem and Blue Earth Diagnostics. Chief Executive Officer of Blue Earth Diagnostics.

Diagnostic 96

Diagnostic Diagnostic Imaging Clinic Radiopharmaceuticals 96

Open Medscience

JUNE 29, 2024

This article reviews key Phase III clinical trials for ALSYMPCA, NETTER-1, and VISION therapies, highlighting advancements in cancer treatment. The post Clinical Trials: Advancements in ALSYMPCA, NETTER-1, and VISION Therapies appeared first on Open MedScience.

Clinic 52

Clinic Radiopharmaceuticals 52

AuntMinnie

FEBRUARY 20, 2024

Blue Earth Therapeutics is highlighting early clinical results from a German trial investigating the use of a lutetium-177 (Lu-177)-labeled prostate specific antigen (PSMA) radiopharmaceutical. A phase I and II clinical trial assessing the safety, tolerability, dosimetry, and antitumor activity of Lu-177 rhPSMA-10.1

Clinic 40

Clinic Nuclear Medicine Radiopharmaceuticals Hospital 40

UCSF Biomedical Imaging

JANUARY 12, 2024

clinical scanners, followed a few years later by a cyclotron which launched our in-house radiopharmaceutical program. In 2003, the Center for Molecular and Functional Imaging (CMFI) at China Basin Landing opened its doors with San Francisco’s first 3T MRI and two 1.5T

Radiopharmaceuticals 122

Radiopharmaceuticals Imaging MRI Clinic 122

AuntMinnie

JUNE 5, 2024

NorthStar Medical Radioisotopes has completed a cleanroom facility at its campus in Beloit, WI, to support batch production of radiopharmaceuticals for research and treatment. The cleanroom at NorthStar's campus in Beloit, WI.

Radiopharmaceuticals 52

Radiopharmaceuticals Clinic Medical IT 52

Imaging Technology

JUNE 7, 2024

milla1cf Fri, 06/07/2024 - 14:57 June 7, 2024 — Shine Technologies, LLC , a pioneer in next-generation fusion-based technology, today announced a new partnership with Blue Earth Therapeutics , a Bracco company and recognized leader in the development of innovative radiopharmaceuticals. Statistically, approximately 12.9%

IT 84

IT Radiopharmaceuticals Clinic Diagnose 84

Imaging Technology

DECEMBER 12, 2023

milla1cf Tue, 12/12/2023 - 10:00 December 12, 2023 — IBA , a world leader in particle accelerator technology and of radiopharmaceutical production solutions is pleased to announce the start of the installation of a Cyclone 30XP in Poland. Beyond At-211, IBA is also pioneering novel accelerator applications for other theranostic isotopes.

Radiopharmaceuticals 111

Radiopharmaceuticals Nuclear Medicine Clinic IT 111

AuntMinnie

MAY 22, 2024

Aktis Oncology has entered a potential $1 billion collaboration agreement with Eli Lilly to generate anticancer radiopharmaceuticals using its miniprotein technology platform. billion in potential preclinical, clinical, regulatory, and commercial milestones, as well as tiered royalties, it noted.

Radiopharmaceuticals 52

Radiopharmaceuticals Clinic IT 52

TTG Imaging Solutions

AUGUST 1, 2023

Martin Shirley was appointed the role of TTG Imaging Solutions Executive Vice President Sales, Marketing & Clinical Operations in April of 2023 as part of TTG Imaging Solutions acquisition of Digirad Health, Inc and its subsidiaries Digirad Diagnostic Imaging, Inc and Digirad Imaging Solution, Inc. The post Martin B.

Nuclear Medicine 40

Nuclear Medicine Clinic Radiopharmaceuticals Diagnostic Imaging 40

TTG Imaging Solutions

AUGUST 1, 2023

Martin Shirley was appointed the role of TTG Imaging Solutions Executive Vice President Sales, Marketing & Clinical Operations in April of 2023 as part of TTG Imaging Solutions acquisition of Digirad Health, Inc and its subsidiaries Digirad Diagnostic Imaging, Inc and Digirad Imaging Solution, Inc. The post Martin B.

Nuclear Medicine 40

Nuclear Medicine Clinic Radiopharmaceuticals Diagnostic Imaging 40

AuntMinnie

JUNE 19, 2024

Voximetry now offers nuclear medicine dosimetry technology as a remote service, with its recent launch of RPT Dosimetry Clinical Services. Incorporating radiopharmaceutical therapy dosimetry typically requires advanced, in-house software, and a trained physics staff, Voximetry said.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Clinic Imaging 52

Imaging Technology

JUNE 11, 2024

She will also raise awareness of nuclear medicine’s value to clinical colleagues and patients and will be laser-focused on breaking down barriers to radiopharmaceutical availability, reimbursement, affordability, and funding. An active SNMMI member, Jacene has been involved in many aspects of the organization.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Patient Care Medical 52

Imaging Technology

JULY 28, 2023

We believe it further validates the clinical utility of POSLUMA in patients with newly diagnosed or recurrent prostate cancer, and can help expand patient access. FDA, as well as on the Phase 3 clinical trial results published recently in the Journal of Urology and European Urology. Chief Executive Officer of the Company. “We

Clinic 84

Clinic Diagnostic Radiopharmaceuticals Radiation 84

AuntMinnie

APRIL 4, 2024

Life Molecular Imaging (LMI) and Sofie Biosciences have begun offering the Neuraceq ( florbetaben F-18) PET radiotracer produced at Sofie's radiopharmaceutical manufacturing site in Cleveland, Ohio. With this expansion, LMI continues driving commercial sales of Neuraceq around the U.S.

Radiopharmaceuticals 95

Radiopharmaceuticals Imaging Disease Diagnostic 95

AuntMinnie

JUNE 11, 2024

TORONTO – The radiopharmaceutical Pluvicto improves progression-free survival in patients with metastatic prostate cancer who haven’t undergone taxane therapy, according to research presented at the SNMMI meeting. Oliver Sartor, MD The study, which was awarded SNMMI’s Abstract of the Year award, shared data from the phase III PSMAfore trial.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiograph Radiographer 122

AuntMinnie

JANUARY 3, 2024

NorthStar Medical Radioisotopes and Chester Springs, PA-based Curadh MTR have entered a strategic collaboration agreement to develop radiopharmaceuticals for the treatment of primary and metastatic solid tumors.

Radiopharmaceuticals 52

Radiopharmaceuticals Diagnostic Clinic Medical 52

Imaging Technology

AUGUST 31, 2023

milla1cf Thu, 08/31/2023 - 15:50 August 31, 2023 — NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals, and Curadh MTR Inc. Ac-225 for use in radiopharmaceutical therapy (RPT). actinium-225 (Ac-225). “As a company at the forefront of U.S.

Medical 90

Medical Radiopharmaceuticals Pharmaceutical Radiation 90

AuntMinnie

DECEMBER 14, 2023

ITM Isotope Technologies Munich has signed a licensing agreement with the life science business of Merck KGaA in Darmstadt, Germany, for the clinical development and commercialization of radiolabeled folate derivatives. The company plans to advance this to phase I clinical testing.

Radiopharmaceuticals 52

Radiopharmaceuticals Clinic Diagnostic Medical 52

Imaging Technology

MAY 23, 2023

milla1cf Tue, 05/23/2023 - 11:36 May 23, 2023 — More than 9 in 10 radiation oncologists report that their practices face clinical staff shortages , according to a new national survey from the American Society for Radiation Oncology ( ASTRO ). Radiation oncologists from across the country are in Washington, D.C. in the past three decades.

Radiation Oncology 69

Radiation Oncology Radiation Clinic Medicare 69

AuntMinnie

JUNE 10, 2024

Evans, a professor in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco, was recognized for his work in biomarker discovery and radiopharmaceutical development.

Nuclear Medicine 40

Nuclear Medicine Radiopharmaceuticals Pharmaceutical Clinic 40

Imaging Technology

AUGUST 28, 2023

The companies will work together to increase near-term production of 225Ac [1] to support ongoing clinical trials and to ensure the large-scale supply of the radioisotope in the long term, addressing growing global demand. Whilst there is high demand, there is a scarcity of 225Ac.

Radiopharmaceuticals 93

Radiopharmaceuticals Pharmaceutical Clinic Medical 93

AuntMinnie

JANUARY 8, 2024

NorthStar will be one of the first commercial-scale producers of actinium-225 for clinical research and commercial radiopharmaceutical therapy, Alpha-9 said. Alpha-9 Oncology and NorthStar Medical Radioisotopes have entered into a supply agreement under which NorthStar will provide Alpha-9 with actinium-225.

Medical 52

Medical Radiopharmaceuticals Clinic Radiology 52

AuntMinnie

OCTOBER 17, 2023

Nucleus RadioPharma has secured $56 million in a Series A funding round to expand production of radiopharmaceutical treatments for cancer patients. Other investors included Echo Global, Fox Chase Cancer Center, Granger Management, Mayo Clinic, Mercy Health, and the University of Missouri.

Radiopharmaceuticals 52

Radiopharmaceuticals Healthcare Healthcare Clinic 52

Imaging Technology

JANUARY 12, 2024

“We are grateful that CMS recognizes the potential of our SCINTIX therapy for patients with all stages of indicated cancers and, with this decision, has addressed provider payment as a barrier to clinical adoption,” continued Powell. Patient treatments also began at several clinical sites in 2023. 1, 2024, to describe SCINTIX therapy.

Radiopharmaceuticals 100

Radiopharmaceuticals Radiation Medicare Clinic 100

Imaging Technology

JULY 5, 2023

Ac-225 is a high energy alpha-emitting radioisotope of increasing interest for clinical studies investigating the use of targeted radiopharmaceutical therapy, which combines select molecules with therapeutic radioisotopes to directly target and deliver therapeutic doses of radiation to destroy cancer cells in patients with serious disease.

Medical 63

Medical Radiopharmaceuticals Pharmaceutical Radiation 63

AuntMinnie

MAY 6, 2024

Artbio, a radiopharmaceutical company developing targeted alpha radioligand therapies, and Nucleus RadioPharma are entering a strategic manufacturing and supply agreement. the companies said.

Radiopharmaceuticals 52

Radiopharmaceuticals Clinic IT 52

AuntMinnie

JANUARY 30, 2024

ITM Isotope Technologies Munich SE and Alpha-9 Oncology have signed a global clinical supply agreement to support the development of Alpha-9's radiopharmaceutical therapy pipeline candidates for cancer treatment.

Radiopharmaceuticals 52

Radiopharmaceuticals Clinic Medical IT 52